• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Growth hormone treatment and risk of recurrence or development of secondary neoplasms in survivors of pediatric brain tumors
【24h】

Growth hormone treatment and risk of recurrence or development of secondary neoplasms in survivors of pediatric brain tumors

机译：小儿脑肿瘤幸存者的生长激素治疗和继发性肿瘤复发或发展的风险

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Growth hormone (GH) is increasingly used for treatment of pediatric brain tumors. However, controversy remains over its safety. This meta-analysis assessed whether GH treatment was associated with risk of recurrence or development of secondary neoplasm for brain tumors in children. Systematic computerized searches of PubMed and Web of Knowledge were performed. Pooled relative risks (RR) with 95% confidence interval (Cl) for recurrence and/or secondary neoplasm in children who were treated with GH versus those who did not receive GH were calculated. Ten studies were included. The pooled recurrence rates were 21.0% and 44.3% in the GH-treated group and non-GH-treated group, respectively. The pooled RR for recurrence was 0.470 (95% CI 0372-0.593; z = 6.33, p = 0.000). Begg's test (p = 0.060) and Egger's test (p = 0.089) suggested there was no significant publication bias. The pooled RR in sensitivity analysis was 0.54 (95% CI 0.37-0.77; z = 3.32, p = 0.001), which showed the result was robust. The pooled RR for secondary neoplasm was 1.838 (95% CI 1.053-3.209; z = 2.14, p = 0.032). Begg's test (p = 1.000) and Egger's test (p = 0.553) suggested there was no significant publication bias. We found no evidence that GH therapy is associated with an increased risk of recurrence for pediatric brain tumors. However, because of our small sample size, the association of GH therapy with an increased risk of secondary neoplasm is uncertain. Further prospective cohorts are needed. (C) 2014 Elsevier Ltd. All rights reserved.
机译：生长激素（GH）越来越多地用于治疗小儿脑瘤。但是，关于其安全性仍存在争议。这项荟萃分析评估了GH治疗是否与儿童脑肿瘤复发或继发性肿瘤发展相关。对PubMed和Web of Knowledge进行了系统的计算机搜索。计算了接受GH治疗的儿童与未接受GH治疗的儿童的复发和/或继发性肿瘤的合并相对危险度（RR），其复发和/或继发性肿瘤的置信区间（Cl）为95％。包括十项研究。 GH治疗组和非GH治疗组的合并复发率分别为21.0％和44.3％。合并复发的RR为0.470（95％CI 0372-0.593; z = 6.33，p = 0.000）。 Begg检验（p = 0.060）和Egger检验（p = 0.089）表明没有明显的出版偏倚。敏感性分析中的合并RR为0.54（95％CI 0.37-0.77; z = 3.32，p = 0.001），表明结果是可靠的。次生肿瘤的合并RR为1.838（95％CI 1.053-3.209; z = 2.14，p = 0.032）。 Begg检验（p = 1.000）和Egger检验（p = 0.553）表明没有明显的出版偏倚。我们没有发现证据表明GH疗法与小儿脑肿瘤复发风险增加有关。但是，由于我们的样本量较小，GH治疗与继发性肿瘤风险增加的关联尚不确定。需要进一步的预期队列。 （C）2014 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号